# Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM

> **NCT05271240** · PHASE3 · RECRUITING · sponsor: **Northwell Health** · enrollment: 432 (estimated)

## Conditions studied

- Glioblastoma
- Glioblastoma Multiforme
- Glioma, Malignant
- GBM
- Brain Cancer
- Glioblastoma, IDH-wildtype
- Glioblastoma Multiforme, Adult

## Interventions

- **DRUG:** Repeated Superselective Intraarterial Cerebral infusion (SIACI) of Bevacizumab (Avastin) with Temozolomide and Radiation
- **DRUG:** Temozolomide and Radiation Alone

## Key facts

- **NCT ID:** NCT05271240
- **Lead sponsor:** Northwell Health
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-04-27
- **Primary completion:** 2027-04-01
- **Final completion:** 2028-04-01
- **Target enrollment:** 432 (ESTIMATED)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05271240

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05271240, "Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05271240. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*